Latest news with #TechnologyandResearch
Yahoo
2 days ago
- Business
- Yahoo
China's clinical trial ecosystem takes centre stage in Suzhou this September
China's rapid emergence as a global clinical trials powerhouse will be in sharp focus this September as leading voices from the biopharma and healthcare sectors convene in Suzhou for the launch of Outsourcing in Clinical Trials China and Clinical Trial Supply China. Held over two days on 3-4 September 2025, the dual event brings together senior executives, regulators, and innovators across R&D, clinical operations, outsourcing, and supply chain to examine the evolving landscape of clinical development in China - arguably the world's most dynamic biopharma market. Strategic inflection point China's clinical trials sector has undergone significant structural transformation over the past five years, driven by a combination of regulatory shifts, capital inflows into biotech, and a shift toward more decentralised, patient-centric trial models. According to GlobalData analysis, China now surpasses the US for annual number of clinical trials. Yet as the ecosystem expands, so too does its complexity - particularly in relation to cross-border compliance, data protection, and clinical logistics. This new industry event marks a pivotal moment, featuring an opening keynote panel on 'The Evolving Clinical Trial Landscape in China: Challenges & Opportunities,' alongside in-depth discussions on artificial intelligence in drug discovery, clinical supply chain management, and geopolitical risk. Sessions will span core operational challenges - including site selection, enhancing collaboration in outsourcing, comparator sourcing, cold chain logistics, and vendor management - as well as broader questions on global collaboration, clinical trial harmonisation, and China's biotech ambitions. The program includes a panel on 'The Rise of Chinese Biotech: A Competitive Challenge for US Companies and Investors,' reflecting growing interest in China's ability to scale R&D innovation, supported by state policy and venture capital. While China continues to make strides in drug discovery and innovation, integration into the global clinical development ecosystem remains uneven. Concerns around IP protection, regulatory uncertainty, and data localisation persist, particularly for international sponsors managing multi-country trials. Speakers from IDA Ireland, Singapore's Agency for Science, Technology and Research, and the US Maryland China Center will participate in a cross-border panel addressing the impact of China's biotech boom on global trials. On 4 September, delegates will have the opportunity to participate in a curated site visit to Biobay, the national biomedical innovation zone located in Suzhou Industrial Park. The tour includes direct engagement with local biotech executives and exposure to platform technologies shaping the next wave of drug development. Confirmed speakers include: Li Zeng, CEO, Jing Medicine Summer Xia, CEO, Trial-Data Medicine Vincent Zang, Senior Director, Clinical Trial Operation, Innovent Bio Angela Yu, Head of Outsourcing, East China Pharm Shen Xiao, CMO, Alebund Siwei Li, Director, Drug Metabolism and Pharmacokinetics, Degron Therapeutics Xiaoyu Deng, Founder, MDCE Medical Megan Qin, Head of Medical Device Clinical Excellence Working Group, CMAC Xiaoyu Deng, Founder, MDCE Medical Claire Qin, Chief Strategy Officer, Intelligen AI Min Geng, Head of Supply Chain, Shanghai Pharma Fiona Barry, Editor in Chief & Director, Globaldata Healthcare Shelly Xie，Associate Director, Clinical & QC Management,Eli Lilly Jinna Qin, President, China Association for Vaccines Daniel Gao, President, ISPE Supply Chain Committee Xiaomei Wang, VP of Clinical Trial Operation, Key Therapharma Yugang Ju, Head of Clinical Operation, Insilico Medicine Quancheng Chen, Agency for Science, Technology and Research, Singapore Chester Xiao, Head of Life Science Industry, IDA Ireland Vikki Wang, Head of China Center, U.S. Maryland China Center View the full list of speakers and the complete conference agenda here. Don't miss this exclusive opportunity to connect with industry leaders, gain actionable insights, and stay ahead in the rapidly evolving clinical trials landscape in China. Join the Outsourcing in Clinical Trials China & Clinical Trial Supply China, happening 3-4 September at the Renaissance Suzhou Hotel. Register here: "China's clinical trial ecosystem takes centre stage in Suzhou this September" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New Indian Express
7 days ago
- Science
- New Indian Express
Lead technology and social transformation, Andhra Guv exhorts students
GUNTUR: Andhra Pradesh Governor S Abdul Nazeer on Saturday called upon graduates of Vignan's Foundation for Science, Technology and Research to become catalysts in India's technological and social transformation. Addressing the university's 13th convocation at its Vadlamudi campus in Guntur district, he said youth are the backbone of national progress and must embrace innovation and responsibility. Highlighting the State's future-focused initiatives, the Governor said Amaravati is being developed not just as an administrative capital but as a 'People's Capital' and a 'Tech and Knowledge City.' He emphasised that the city is being shaped with smart infrastructure, sustainable development, and citizen-centric digital governance, positioning it as a symbol of technological excellence. He also spotlighted the 'Quantum Valley' project, aimed at establishing Andhra Pradesh as a global centre for quantum technologies. With strategic partnerships and a clear vision, the initiative is expected to boost the state's economy and reinforce India's global presence in emerging technologies. Lauding Vignan University's interdisciplinary approach, merging fields like engineering and humanities, agriculture and AI, and design and law, the Governor stressed the importance of fostering innovation over merely awarding degrees. Quoting Dr. A.P.J. Abdul Kalam, he encouraged students to view setbacks as learning opportunities. A total of 2,122 degrees were conferred, including 60 gold medals and special awards for academic excellence and leadership. Honorary doctorates were awarded to iLabs founder Chintalapati Srinivasaraju, Zen Technologies MD Ashok Atluri, and music composer Dr. Komanduri Ramachari.
Business Times
31-07-2025
- Business
- Business Times
Apac biotech sector could draw capital as investors seek diversification amid US-China tensions
[SINGAPORE] Asia-Pacific could be the new frontier for biotechnology investment, a report by consulting firm Bain & Company indicated on Thursday (Jul 31). Markets in the region are gaining ground as credible innovation hubs as global biotech strategies shift amid geopolitical tensions and deep US research funding cuts, according to the report. The report was developed jointly with the Economic Development Board, the Agency for Science, Technology and Research, JPMorgan and SG Growth Capital. 'The potential for US-based scientific talent to migrate to more favorable regions could also create an opportunity for Asia-Pacific governments and institutions to strengthen their innovation bases,' the report indicated. Favorable intellectual property regimes, regulatory agility and tax incentives – particularly in Singapore – position Apac as an attractive destination for global biotech investment, it added. Moreover, the region is winning recognition for next-generation modalities, from mRNA and cell and gene therapies to artificial intelligence-enabled drug discovery. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Fabio La Mola, partner at Bain & Company, said: 'We are looking at an exciting era for Apac's biotech sector, with the opportunity for true innovation to emerge from a geography that historically has been primarily a commercialization hub.' China leads, but geopolitical conflict pull capital away China dominates Apac's biotech investment scene, but geopolitical developments could divert capital elsewhere, said Bain & Company. The country accounted for more than 75 per cent of regional biotech venture capital and private equity flows since 2019, and industry giants like Pfizer and AstraZeneca are committing billions to research and development facilities in China, according to the report. With stunning strides over recent years, China's biotech sector is poised to challenge Western dominance on innovation. Notably, the number of Chinese novel drugs entering into development surpassed that of the European Union in 2024. However, the report noted that geopolitical tensions are reshaping biotech strategies, with biotech funding activity in China having slowed over the past few months. Amid fraught US-China relations, US pharmaceutical firms are rethinking their reliance on China and are seeking diversification to hedge against risk, Bain & Company said. 'While China continues to offer significant advantages in cost efficiency and scale, persistent geopolitical tensions and mounting policy uncertainty are diversifying capital flows into emerging hubs like Singapore and South Korea,' the company said. 'China has long been Asia-Pacific's biotech leader in terms of scale, but Singapore is emerging due to its commitment to innovation, political neutrality, intellectual property protection, and regulatory alignment,' it added. Slowing US-led innovation in early-stage R&D funding presents opportunity for Apac As tightening research budgets threaten to slow US-led innovation, particularly in early-stage academic research, Apac markets could step in to fill the gap, the report said. This comes as proposed funding cuts at the US National Institutes of Health are expected to reduce grant availability. 'As a result, Apac markets are increasingly positioned to lead in early-stage research, with big pharma likely to turn more actively to the region for sourcing innovation,' Bain & Company said. The report indicated that public funding plays an increasingly important role in supporting early-stage research, given that capital tends to flow toward later-stage, clinically-validated biotech deals, as higher investor risk aversion has led to a preference for more mature projects with clearer commercialisation pathways. This is seen in how early stage funding in Apac declined at an 11 per cent compound annual growth rate from 2019 to 2024, while late-stage biotech deal volumes grew 1.5 times. In response to the early-stage R&D funding gap, Apac governments are stepping up to seizing on the opportunity. They are launching targeted programmes providing capital and infrastructure that supports early-stage R&D projects to attract private capital investment flows to their markets. For instance, the Korea Drug Development Fund has committed US$1.6 billion to over 1,200 projects by 2030, while Japan's Bioventure Support Program is deploying US$366 million to nurture biotech startups. In Singapore, the government has allocated S$28 billion to support science and technology development, including biomedical R&D under the ongoing Research, Innovation, and Enterprise plan.
Business Insider
29-07-2025
- Business
- Business Insider
How IBM Is Helping AI Models Improve Their Social Skills
Large language models (LLMs) are beginning to move past simple question-and-answer tasks and into more complex scenarios that involve reasoning, strategy, and even social skills. Indeed, a new open-source platform called TextArena was created in order to train AI for situations that require these skills. Developed by researchers from Singapore's Agency for Science, Technology and Research (A*STAR) and tech giant IBM (IBM), the platform allows LLMs to compete in over two dozen text-based games that are similar to classic computer puzzles and board games from the 1980s that test abilities like negotiation, planning, and problem solving. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Interestingly, TextArena acts as a training ground where AI agents can learn through interaction rather than memorization. By using reinforcement learning, the platform measures performance and updates leaderboards in real time. This approach simulates real-world conditions more effectively than fixed exams and provides a nearly endless stream of data for improving models. Furthermore, since its launch in January, TextArena has grown quickly and has hosted more than 100,000 matches for 216 competing models. It is also worth noting that the project has drawn a lot of interest from the open-source community, which has helped expand its game library and refine the user experience. This shows just how excited people are about teaching AI to handle social interactions that could make it more practical in everyday life. By focusing on cooperation, mind theory, and negotiation, TextArena is helping LLMs develop the softer skills needed to interact better with humans. Is IBM a Buy, Sell, or Hold? Turning to Wall Street, analysts have a Moderate Buy consensus rating on IBM stock based on seven Buys, four Holds, and one Sell assigned in the past three months, as indicated by the graphic below. Furthermore, the average IBM price target of $297.33 per share implies 13% upside potential.
Arab Times
22-07-2025
- Health
- Arab Times
AI-powered model to predict liver cancer recurrence
SINGAPORE, July 22, (Xinhua): Singaporean researchers have developed an artificial intelligence-powered scoring system capable of predicting the recurrence of liver cancer, according to a press release from the Agency for Science, Technology and Research on Monday. Developed by scientists from the Institute of Molecular and Cell Biology (IMCB) under the agency in collaboration with the Singapore General Hospital, the system can forecast the recurrence of hepatocellular carcinoma, the most common type of liver cancer, with approximately 82 percent accuracy. The system works by analyzing the spatial distribution of natural killer immune cells and five key genes within liver tumor tissues. "In Singapore, up to 70 percent of liver cancer patients experience recurrence within five years," said Principal Investigator Joe Yeong from the IMCB, noting that this system empowers clinicians to intervene as early as possible. Researchers validated the system using tissue samples from 231 patients across five hospitals. It is now accessible via a free web portal for research purposes, with plans underway to integrate it into standard clinical workflows.
